Indirect Network Meta-Analysis Ranks Cardiorenal Drugs in Diabetic CKD
This network meta-analysis clarifies relative, though indirect, cardiorenal effects of the three major protective drug classes to guide individualized selection in type 2 diabetes with chronic kidney disease.
SGLT2 inhibitors show promise for renal outcomes in T2D-CKD.
The study evaluates potential cardiovascular and renal benefits and safety profiles of GLP-1 receptor agonists (GLP-1RAs), sodium-glucose co-transporter 2 inhibitors (SGLT2is), and non-steroidal mineralocorticoid receptor antagonists (nsMRAs) in patients with type 2 diabetes and chronic kidney disease (T2D-CKD). SGLT2is showed greater reductions in major kidney outcomes and hospitalization for heart failure compared to nsMRAs and GLP-1RAs, while GLP-1RAs were more favorable for cardiovascular death. Indirect comparisons suggest SGLT2is may offer better renal benefits, but confidence in evidence is low to moderate. Direct comparative trials are needed for conclusive guidance. SGLT2 inhibitors may provide superior renal outcomes in T2D-CKD, yet direct head-to-head trials are needed.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Chen H, Wu X, Yuan M, Ren F, Liu T, Yang L, An X, Zhan Y
Citation:Chen H, Wu X, Yuan M, et al. Efficacy and safety of GLP-1RAs, SGLT2is, and nsMRAs for cardiovascular and renal outcomes in T2DM with CKD: a systematic review and network meta-analysis. Frontiers in endocrinology. 2026;17:1937754. doi:10.3389/fendo.2026.1937754